Clinical Trial Update: Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study [Phase 1]

View source ↗

Summary

Long-term safety results from a Phase 1 extension study of SyB L-1101 in patients with recurrent/relapsed or refractory myelodysplastic syndromes; results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• SyB L-1101 (L-1101)

Snippet

Sponsor: SymBio Pharmaceuticals | Conditions: Myelodysplastic Syndrome | Phase 1 | Status: COMPLETED | Results posted: 2017-03-31